ALK and non-small cell lung carcinoma: A study enrolled 92 ALK+ NSCLC patients, utilizing plasma cfDNA NGS for longitudinal monitoring, correlating the absence of baseline circulating tumor DNA (ctDNA) with longer PFS and OS [149].